Newron Pharmaceuticals S.p.A. (0QOI.L)
CHF 7.54
(6.95%)
CHF 7.54
(6.95%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -11.62 Million EUR | 12.58% |
| 2022 | -13.3 Million EUR | -7.65% |
| 2021 | -12.35 Million EUR | 31.6% |
| 2020 | -18.06 Million EUR | 13.56% |
| 2019 | -20.89 Million EUR | -39.53% |
| 2018 | -14.97 Million EUR | -265.67% |
| 2017 | -4.09 Million EUR | 73.27% |
| 2016 | -15.32 Million EUR | 13.3% |
| 2015 | -17.67 Million EUR | -94.44% |
| 2014 | -9.09 Million EUR | -16.9% |
| 2013 | -7.77 Million EUR | -188.32% |
| 2012 | -2.69 Million EUR | 58.39% |
| 2011 | -6.48 Million EUR | 70.05% |
| 2010 | -21.64 Million EUR | 11.87% |
| 2009 | -24.55 Million EUR | -34.05% |
| 2008 | -18.31 Million EUR | -33.9% |
| 2007 | -13.68 Million EUR | 18.33% |
| 2006 | -16.75 Million EUR | -11.12% |
| 2005 | -15.07 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -7.68 Million EUR | 0.0% |
| 2023 Q2 | -4.3 Million EUR | 0.0% |
| 2023 FY | -11.62 Million EUR | 12.58% |
| 2023 Q4 | -7.32 Million EUR | 0.0% |
| 2022 FY | -13.3 Million EUR | -7.65% |
| 2022 Q2 | -6.45 Million EUR | 0.0% |
| 2022 Q4 | -6.84 Million EUR | 0.0% |
| 2021 Q2 | -7.88 Million EUR | 0.0% |
| 2021 Q4 | -4.46 Million EUR | 0.0% |
| 2021 FY | -12.35 Million EUR | 31.6% |
| 2020 FY | -18.06 Million EUR | 13.56% |
| 2020 Q4 | -8.09 Million EUR | 0.0% |
| 2020 Q2 | -9.96 Million EUR | 0.0% |
| 2019 Q4 | -6.45 Million EUR | 0.0% |
| 2019 FY | -20.89 Million EUR | -39.53% |
| 2019 Q2 | -14.44 Million EUR | 0.0% |
| 2018 Q2 | -7.59 Million EUR | 0.0% |
| 2018 Q4 | -7.38 Million EUR | 0.0% |
| 2018 FY | -14.97 Million EUR | -265.67% |
| 2017 Q2 | 2.33 Million EUR | 0.0% |
| 2017 FY | -4.09 Million EUR | 73.27% |
| 2017 Q4 | -6.43 Million EUR | 0.0% |
| 2016 Q2 | -8.87 Million EUR | 0.0% |
| 2016 FY | -15.32 Million EUR | 13.3% |
| 2016 Q4 | -6.44 Million EUR | 0.0% |
| 2015 FY | -17.67 Million EUR | -94.44% |
| 2015 Q2 | -6.84 Million EUR | 0.0% |
| 2015 Q4 | -10.83 Million EUR | 0.0% |
| 2014 Q4 | -4.32 Million EUR | 0.0% |
| 2014 FY | -9.09 Million EUR | -16.9% |
| 2014 Q2 | -4.76 Million EUR | 0.0% |
| 2013 Q4 | -3.28 Million EUR | -70.36% |
| 2013 FY | -7.77 Million EUR | -188.32% |
| 2013 Q3 | -1.92 Million EUR | 19.86% |
| 2013 Q2 | -2.4 Million EUR | 0.0% |
| 2012 Q1 | -620.25 Thousand EUR | 0.0% |
| 2012 Q2 | -620.25 Thousand EUR | 0.0% |
| 2012 FY | -2.69 Million EUR | 58.39% |
| 2012 Q3 | -620.25 Thousand EUR | 0.0% |
| 2012 Q4 | -1.92 Million EUR | -210.88% |
| 2011 Q3 | -1.6 Million EUR | 0.0% |
| 2011 Q1 | -1.6 Million EUR | 0.0% |
| 2011 Q2 | -1.6 Million EUR | 0.0% |
| 2011 FY | -6.48 Million EUR | 70.05% |
| 2011 Q4 | -620.25 Thousand EUR | 61.42% |
| 2010 Q3 | -5.41 Million EUR | 0.0% |
| 2010 FY | -21.64 Million EUR | 11.87% |
| 2010 Q1 | -5.41 Million EUR | 0.0% |
| 2010 Q4 | -1.6 Million EUR | 70.33% |
| 2010 Q2 | -5.41 Million EUR | 0.0% |
| 2009 Q4 | -5.41 Million EUR | 11.0% |
| 2009 FY | -24.55 Million EUR | -34.05% |
| 2009 Q3 | -6.08 Million EUR | 0.0% |
| 2009 Q2 | -6.08 Million EUR | 0.0% |
| 2009 Q1 | -6.08 Million EUR | 0.0% |
| 2008 Q2 | -4.08 Million EUR | 0.0% |
| 2008 Q1 | -4.08 Million EUR | 0.0% |
| 2008 FY | -18.31 Million EUR | -33.9% |
| 2008 Q4 | -6.08 Million EUR | -48.88% |
| 2008 Q3 | -4.08 Million EUR | 0.0% |
| 2007 Q3 | -2.77 Million EUR | 0.0% |
| 2007 Q2 | -2.77 Million EUR | 0.0% |
| 2007 Q1 | -2.77 Million EUR | 0.0% |
| 2007 FY | -13.68 Million EUR | 18.33% |
| 2007 Q4 | -4.08 Million EUR | -47.51% |
| 2006 FY | -16.75 Million EUR | -11.12% |
| 2006 Q1 | -4.18 Million EUR | 0.0% |
| 2006 Q3 | -4.18 Million EUR | 0.0% |
| 2006 Q2 | -4.18 Million EUR | 0.0% |
| 2006 Q4 | -2.77 Million EUR | 33.81% |
| 2005 Q3 | -3.76 Million EUR | 0.0% |
| 2005 Q1 | -3.76 Million EUR | 0.0% |
| 2005 Q2 | -3.76 Million EUR | 0.0% |
| 2005 FY | -15.07 Million EUR | 0.0% |
| 2005 Q4 | -4.18 Million EUR | -11.12% |
| 2004 Q4 | -3.76 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Relief Therapeutics Holding AG | -110.82 Million CHF | 89.507% |
| Tecan Group AG | 135.96 Million CHF | 108.553% |
| Santhera Pharmaceuticals Holding AG | 68.84 Million CHF | 116.892% |
| Basilea Pharmaceutica AG | 19.2 Million CHF | 160.552% |
| Bachem Holding AG | 129.38 Million CHF | 108.988% |
| Siegfried Holding AG | 172.06 Million CHF | 106.758% |
| Molecular Partners AG | -61.1 Million CHF | 80.97% |